VRTX241213P475000
- 20.22
- 0.000.00%
Vertex Pharmaceuticals Newsroom
Market Mixed on Friday the 13th | Livestock
$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today
Thursday Ends in Index Declines | Wall Street Today
Market Falls Thursday, Producer Inflation Grows, and Tech Pulls Back From Records | LiveStock
TD Cowen Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $525
TD Cowen Keeps Their Buy Rating on Vertex Pharmaceuticals (VRTX)
Market Climbs on CPI Inflation and Likelihood of Rate Cuts | Livestock
Vertex Pharmaceuticals (VRTX) Falls More Steeply Than Broader Market: What Investors Need to Know
Market Falls Wednesday, but Googles Chip Impresses | WST
10 Health Care Stocks With Whale Alerts In Today's Session
Google's Quantum Chip Might Have Contacted Parallel Universes | Live Stock
Jefferies follows JPMorgan's call on Vertex Pharmaceuticals (VRTX.US) and raises the target price to $550.
Based on fundamentals and product pipeline, jefferies financial has upgraded vertex pharmaceuticals to buy.
Vertex Upgraded to Buy by Jefferies on Fundamentals, Pipeline
Vertex Has $5 Billion-Plus Opportunity In Pain And Kidney Disease Programs, Analyst Upgrades Stock
Vertex Reports Positive Long-term Data for Casgevy
Monday Market Falls, Chinese Stocks Climb, Indices Rebalance | Live Stock
A Glimpse Into The Expert Outlook On Vertex Pharmaceuticals Through 19 Analysts
Vertex Pharmaceuticals Raised to Buy From Hold by Jefferies
Vertex Pharmaceuticals Analyst Ratings
Jefferies Upgrades Vertex Pharmaceuticals to Buy From Hold, Adjusts Price Target to $550 From $500